Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment
Gabriel Ghiaur, Mark J. Levis
Hematology/Oncology Clinics of North America (2017) Vol. 31, Iss. 4, pp. 681-692
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

A review of FLT3 inhibitors in acute myeloid leukemia
Jennifer Zhao, Sonal Agarwal, Hiba Ahmad, et al.
Blood Reviews (2021) Vol. 52, pp. 100905-100905
Open Access | Times Cited: 122
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Yixiang Gu, Ruifeng Yang, Yang Zhang, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access | Times Cited: 6
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Irene M. Ghobrial, Alexandre Detappe, Kenneth C. Anderson, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 4, pp. 219-233
Closed Access | Times Cited: 144
New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise
Stephan Bohl, Lars Bullinger, Frank G. Rücker
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1983-1983
Open Access | Times Cited: 80
FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance
Zhijie Wang, Jiongheng Cai, Jie Cheng, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 6, pp. 2878-2900
Closed Access | Times Cited: 64
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 12
Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
Silvia Maifrede, Margaret Nieborowska-Skorska, Katherine Sullivan-Reed, et al.
Blood (2018) Vol. 132, Iss. 1, pp. 67-77
Open Access | Times Cited: 67
Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers
Marie Brachet‐Botineau, Marion Polomski, Heidi A. Neubauer, et al.
Cancers (2020) Vol. 12, Iss. 1, pp. 240-240
Open Access | Times Cited: 66
FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells
Nathalie Javidi-Sharifi, Jacqueline Martinez, Isabel English, et al.
eLife (2019) Vol. 8
Open Access | Times Cited: 65
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
Dilana E. Staudt, Heather C. Murray, Tabitha McLachlan, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 3198-3198
Open Access | Times Cited: 63
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Motoki Eguchi, Yosuke Minami, Ayumi Kuzume, et al.
Biomedicines (2020) Vol. 8, Iss. 8, pp. 245-245
Open Access | Times Cited: 57
Role of Biomarkers in FLT3 AML
Nitika Nitika, Jiao Wei, Ai‐Min Hui
Cancers (2022) Vol. 14, Iss. 5, pp. 1164-1164
Open Access | Times Cited: 32
Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia
Eleni E Ladikou, Timothy Chevassut, Chris Pepper, et al.
British Journal of Haematology (2020) Vol. 189, Iss. 5, pp. 815-825
Open Access | Times Cited: 45
Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
Yvyin Zhang, Peihong Wang, Yang Wang, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 14
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia
Alireza Mohebbi, Fahimeh Shahriyary, Vida Farrokhi, et al.
Leukemia Research (2024) Vol. 141, pp. 107505-107505
Closed Access | Times Cited: 5
Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia
Luyao Long, Yehuda G. Assaraf, Zi‐Ning Lei, et al.
Drug Resistance Updates (2020) Vol. 52, pp. 100703-100703
Closed Access | Times Cited: 37
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
Melisa Tecik, Aysun Adan
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1449-1478
Open Access | Times Cited: 22
Concurrent inhibition of FLT3 and sphingosine kinase-1 triggers synergistic cytotoxicity in midostaurin resistant FLT3-ITD positive acute myeloid leukemia cells via blocking FLT3/STAT5A signaling to induce apoptosis
Melisa Tecik, Aysun Adan
Journal of Chemotherapy (2025), pp. 1-17
Closed Access
Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner
Tianzhuo Zhang, Danna Wei, Yun Zhan, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia
Xue Yuan, Yong Chen, Wanhua Zhang, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 8, pp. 4158-4173
Closed Access | Times Cited: 34
<p>Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date</p>
Luke B. Fletcher, Sunil K. Joshi, Elie Traer
Cancer Management and Research (2020) Vol. Volume 12, pp. 151-163
Open Access | Times Cited: 30
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
Salvatore Perrone, Tiziana Ottone, Nadezda Zhdanovskaya, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 2, pp. 223-38
Open Access | Times Cited: 10
The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia
Tingyong Cao, Nenggang Jiang, Hongyan Liao, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 28
Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Jan Philipp Bewersdorf, Maximilian Stahl, Amer M. Zeidan
Leukemia & lymphoma/Leukemia and lymphoma (2019) Vol. 60, Iss. 6, pp. 1354-1369
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top